Ray Therapeutics receives EMA PRIME status for gene therapy

Pharmaceutical Technology

Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).

pharminent April 30, 2026 (Last updated: April 30, 2026)

Pharmaceutical Technology

Ray Therapeutics has received PRIME designation from the EMA for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).

Related Stories